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PAPADOPOULOS ETAL 3METHODS: An online survey was sent to members of the
Pediatric Asthma in Real Life think tank and the World Allergy
Organization Pediatric Asthma Committee. It included
questions on service provision, disease burden, and the clinical
course of confirmed cases of COVID-19 infection among chil-
dren with asthma.
RESULTS: Ninety-one respondents, caring for an estimated
population of more than 133,000 children with asthma,
completed the survey. COVID-19 significantly impacted pedi-
atric asthma services: 39% ceased physical appointments, 47%
stopped accepting new patients, and 75% limited patients’ visits.
Consultations were almost halved to a median of 20 (inter-
quartile range, 10-25) patients per week. Virtual clinics and
helplines were launched in most centers. Better than expected
disease control was reported in 20% (10%-40%) of patients,
whereas control was negatively affected in only 10% (7.5%-
12.5%). Adherence also appeared to increase. Only 15 confirmed
cases of COVID-19 were reported among the population; the
estimated incidence is not apparently different from the reports
of general pediatric cohorts.
CONCLUSIONS: Children with asthma do not appear to be
disproportionately affected by COVID-19. Outcomes may even
have improved, possibly through increased adherence and/or
reduced exposures. Clinical services have rapidly responded to
the pandemic by limiting and replacing physical appointments
with virtual encounters.  2020 American Academy of Allergy,
Asthma & Immunology (J Allergy Clin Immunol Pract 2020;-
:---)
Key words: Asthma; Children; Virus; Adherence; COVID-19;
SARS-CoV2; ControlINTRODUCTION
The ongoing coronavirus disease 2019 (COVID-19)
pandemic, induced by severe acute respiratory syndrome coro-
navirus 2 (SARS-CoV-2), is driving an unprecedented interna-
tional research and clinical mobilization, to understand and
contain the disease.1 COVID-19 has less direct impact on chil-
dren and adolescents than on adults, although all ages are
affected.2 In children, as in adults, preexisting chronic conditions
appear to increase the risk for severe or fatal disease.3,4 Despite
initial clinical reports that did not identify asthma to be over-
represented among patients with COVID-19,5 it has been sug-
gested that asthma, particularly when uncontrolled, may be
included among the underlying conditions imposing a risk for
severe COVID-19.3 Further evaluation is urgently required,
because children with wheezing illness/asthma constitute a sig-
nificant proportion throughout the pediatric age span and
asthma is the most frequent chronic condition managed by
pediatricians.6,7
To rationalize management and instruct the public health care
system, it is crucial to understand whether asthma, allergy, or
their treatments add risk, protect, or have no discernible effects
on the health of children with asthma.8,9
Symptoms of COVID-19 in children usually include dry
cough and often fever. In contrast with infected adults, most
infected children appear to have a milder clinical course.10
Dyspnea may be present; however, wheeze has not been re-
ported as part of the clinical presentation.2,11,12 There iscurrently no published information about the clinical course or
other characteristics of COVID-2019 in children with asthma.
In parallel, the COVID-19 pandemic introduced a need to
change clinical practice, including minimizing face-to-face con-
tact and limiting the use of aerosolising procedures.13 A need for
guidelines in the context has been expressed14; however, this is
challenged by the lack of evidence.
In this context, pediatric asthma services around the world are
being reorganized to face the new, uncertain, reality. Pediatric
Asthma in Real Life, a think tank initiated by the Respiratory
Effectiveness Group, comprising pediatric asthma experts from
all around the world, aims to develop recommendations that will
improve patient care.15 To identify and share best practices, and
in collaboration with the World Allergy Organization Pediatric
Asthma Committee, we assessed the impact of COVID-2019 on
pediatric asthma services and their patients through a survey
addressed to large pediatric asthma clinics worldwide.METHODS
An online questionnaire was constructed with input from the
Pediatric Asthma in Real Life steering group. It included questions
about the operation of pediatric asthma clinics during the COVID-
19 pandemic, changes in the methods used to communicate with
and assess patients, estimates of overall disease activity and patient
attitudes, as well as known cases of COVID-19 infection, within the
respondents’ pediatric asthma cohorts. The survey questionnaire can
be found in Table E1 in this article’s Online Repository at www.jaci-
inpractice.org. Sixty-two members of the participating groups,
actively involved in the assessment and management of children with
asthma, as assessed by a previous survey,15 and representing clinical
services in different health care systems, were invited to complete the
survey on April 9, 2020. The recipients were allowed to further
forward the survey to additional clinical practices in their country.
Because of the extraordinary circumstances and urgency, the allowed
response time was 10 days; no reminders were sent.
Responses are presented descriptively, as proportions or median
(interquartile range [IQR]) for numeric variables. We report perti-
nent differences in the responses across different responder groups:
A. Participants from countries with different COVID burden: (1)
less than 10 deaths per million population (limited burden), (2)
between 10 and 100 deaths per million population (intermediate
burden), and (3) more than 100 deaths per million population
(high burden), as of April 19, 2020, the last day of the survey.
B. Participants from different continents. Adequate responses were
collected from the Americas, Asia, and Europe, which allowed
meaningful comparisons.
C. Participants from countries with different economies. Countries
with high versus low and middle income, according to the World
Bank classification.
D. Participants from different practice settings, namely, primary
care/private clinics, secondary care, and tertiary/university
hospitals.
We used Fisher exact test for comparing dichotomous data, given
the relatively limited number of participants in each group. Kruskal-
Wallis test was used for comparing continuous data, assuming a non-
normal distribution. Between-group differences were formally tested
only for findings around asthma control and treatment adherence, to
avoid multiple comparisons and the risk of type 1 and/or type 2
statistical error. In an exploratory analysis, we extrapolated the
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4 PAPADOPOULOS ETALestimates of respondents about asthma control, treatment changes,
and treatment adherence in their actual case numbers during the
preceding month and we present the risk ratios of patients with
favorable versus unfavorable outcomes. Given the limitations of this
analysis, we chose to use the 99% CIs.
Although completion of questions was optional, each question
was answered by more than 75% of the eligible participants for that
question. Missing responses data were disregarded when evaluating
the findings.RESULTS
Survey responses and patient population
represented
All invited responded to the survey; response from additional
centers, invited by the participants, led to an overall response rate
of 146% over the original invitations. Ninety-one experts, each
representing a different clinical practice from different care set-
tings, economies, and countries, including the whole spectrum of
COVID-19 disease burden, completed the survey. Respondents
were from 27 countries and 5 continents (Africa, Asia, Americas,
Europe, and Oceania), consulting a median of 20 (IQR, 10-25)
children with asthma per week, corresponding to 89,804 annual
visits in the 61 centers reporting this question, or an estimated
133,969 visits in the complete cohort. Characteristics of the
respondent’s practices are summarized in Tables I and II and in
Tables E2 to E4 in this article’s Online Repository at www.jaci-
inpractice.org.
Effect of the COVID-19 pandemic on pediatric
asthma practices worldwide
Over the recent time period, pediatric asthma clinics across
the world have markedly changed their practice because of the
COVID-19 pandemic (Table I). Almost half the participants
(47%) reported that their clinics did not accept/receive new
patients during the epidemic, with responders from Asia being
a notable exception, as 78% received new patients. Among the
participating practices, 39% have ceased physical appoint-
ments; this proportion exceeded 60% in the more heavily
burdened countries. Among centers that continued to run
physically, 75% reported a decrease in the number of evaluated
cases during the pandemic period. During the month preced-
ing the completion of the survey, participants reviewed a me-
dian of 35 cases (IQR, 20-60), approximately half their normal
rate, in parallel to the escalating measures to avoid patient
contact.
In pediatric asthma clinics that continued accepting physical
appointments, several practice changes were implemented to
minimize these encounters. Further to the reduction of evaluated
cases, most (62%) clinics limited the frequency of planned
monitoring encounters, with 28% reviewing only children with
severe asthma, while 8% accepted only patients receiving bi-
ologics. Access to asthma medications was an issue in 30% of the
participating centers, predominantly in Asia (44%).
Importantly, more than 90% of participating centers have
launched virtual online or telephone consultations to substitute
or complement clinical visits, while 73% have used a helpline to
address the needs of their patients. About half the participants
considered virtual visits a suboptimal clinical encounter, viable
only in the short-term. Nevertheless, a considerable proportion
(42%) found them acceptable, or, occasionally, as good asface-to-face visits. Several tools were used by all respondents to
facilitate better distal monitoring of asthma control. Validated
tools for evaluating asthma control, such as the Asthma Control
Test or the Asthma Control Questionnaire, were used by 72% of
the participants. Peak expiratory flow readings (31%) or portable
spirometer readings (8.5%) were less often used, while treatment
adherence was formally monitored in 42% of practices. Symp-
tom recording apps or telemedicine platforms were used in 27%
of centers.
There were some between-group differences in monitoring.
First, validated asthma control questionnaires were less favored in
private/primary care practices (33%), compared with proportions
exceeding 80% in secondary, tertiary, and university hospitals.
On the contrary, 67% of the private practices opted for tele-
medicine platforms, in contrast to only 28% of the clinics in
secondary care and 13% of the university/tertiary care hospitals.
Peak expiratory flow rate was more often used in less affluent
countries (42% in low-/middle- vs 27% in high-income coun-
tries), while portable spirometers were solely available in high-
income countries. Treatment adherence was more extensively
evaluated in Asia (78%), than in Europe (44%), or in the
Americas (16%).Pediatric asthma burden during the COVID-19
pandemic
Evaluation on pediatric asthma burden during the pandemic
was queried as proportions improving, remaining stable, or
worsening within each individual clinic, for a number of clini-
cally relevant aspects (Table II). Within each practice, a median
of 70% (IQR, 60%-80%) of evaluated patients were well
controlled, 20% (IQR, 10%-30%) partially controlled, and 10%
(IQR, 0%-10%) uncontrolled. In subjectively evaluating their
patients’ asthma control status, participants considered that while
in 85% (IQR, 70%-100%) of cases this was in line with their
previous symptom trajectories (as expected), in 20% (IQR, 10%-
40%) this exceeded their expectations, while control had dete-
riorated in only 10% (IQR, 7.5%-12.5%). The risk ratio of the
children with better than expected versus worse than expected
asthma control was 2.69 (99% CI, 2.17-3.34), while all sub-
group analyses yielded consistent findings. Apart from the pre-
specified subgroup analyses (by the countries’ COVID-19
burden, countries’ economy, continent, and clinical setting), we
evaluated separately centers using or not using a validated
questionnaire for evaluating asthma control and centers formally
evaluating treatment adherence or not. In line with this
impression of the clinical status, no treatment changes were
required for 80% of patients (IQR, 60%-90%), while a similar
proportion of patients (w10%) required treatment escalation or
deescalation. Treatment adherence was estimated to be un-
changed in 80% (IQR, 60%-100%) of patients, whereas it
improved in 20% (IQR, 10%-40%) of children with asthma,
especially in the Americas (IQR, 20%-63%). Reduced adherence
was reported in only up to 10% of patients (IQR, 0%-10%).
Increased treatment adherence was consistently observed both in
the overall study population (relative risk, 1.97; 99% CI, 1.66-
2.33) and in all the subgroup analyses.
Countries that were less severely hit by the COVID-19
epidemic reported a higher proportion of well-controlled pa-
tients. However, there were no between-group differences in the
expected symptom trajectories.
TABLE I. Effects of the COVID-19 pandemic on pediatric asthma practices
Pediatric asthma clinics metrics Overall cohort
COVID-19 burden (deaths/million) Clinical setting
<10 10-100 >100 Primary Secondary Tertiary/university
No. of participants in each category, N 91 31 15 26 15 11 47
Measures to limit physical contact
Did not receive/accept new cases during pandemic 33/70 (47) 13/25 (52) 6/15 (40) 13/25 (52) 5/15 (33) 7/11 (64) 20/40 (50)
Ceased physical appointments 35/91 (39) 11/31 (35) 4/15 (27) 16/26 (62) 8/15 (53) 3/11 (27) 21/47 (45)
Reduced no. of cases* 39/52 (75) 15/20 (75) 9/11 (82) 8/10 (80) 6/7 (86) 5/8 (63) 21/26 (81)
Reduced planned monitoring visits* 32/52 (62) 12/20 (60) 8/11 (73) 5/10 (50) 6/7 (86) 5/8 (63) 14/26 (54)
Only monitoring patients receiving biologics 6/71 (9) 1/25 (4) 0/15 (0) 3/25 (12) 1/15 (7) 0/11 (0) 4/40 (10)
Only monitoring children with severe asthma 20/71 (28) 4/25 (16) 7/15 (47) 8/25 (32) 2/15 (13) 2/11 (18) 15/40 (38)
Nonphysical services launched to address health needs
Launched virtual online or telephone consultations 79/87 (91) 25/31 (81) 15/15 (100) 25/26 (96) 15/15 (100) 11/11 (100) 40/47 (85)
Launched helpline for children with asthma 57/78 (73) 23/31 (74) 10/15 (67) 19/26 (73) 11/15 (73) 9/11 (82) 33/47 (70)
Shared any advisory material 45/78 (58) 22/31 (71) 6/15 (40) 13/26 (50) 11/15 (73) 8/11 (73) 23/47 (49)
Shared advisory material via email 24/78 (31) 8/31 (26) 4/15 (27) 11/26 (42) 5/15 (33) 4/11 (33) 14/47 (30)
Shared advisory material via social media 18/78 (23) 12/31 (39) 2/15 (13) 1/26 (4) 4/15 (27) 6/11 (55) 5/47 (11)
Shared advisory material through Web site 14/78 (18) 7/31 (23) 1/15 (7) 3/26 (12) 3/15 (20) 2/11 (19) 7/47 (15)
Tools for evaluating asthma control
Using at least 1 tool for evaluating asthma control 71/71 (100) 25/25 (100) 15/15 (100) 25/25 (100) 15/15 (100) 11/11 (100) 40/40 (100)
A validated questionnaire, such as ACT or ACQ 51/71 (72) 16/25 (64) 11/15 (73) 20/25 (80) 5/15 (33) 9/11 (82) 33/40 (83)
A standardized questionnaire 19/71 (27) 4/25 (16) 5/15 (33) 9/25 (36) 1/15 (7) 1/11 (9) 16/40 (40)
Peak flow meter reading 22/71 (31) 10/25 (40) 6/15 (40) 4/25 (16) 5/15 (33) 4/11 (36) 11/40 (28)
Portable spirometer reading 6/71 (9) 0/25 (0) 3/15 (20) 1/25 (4) 0/15 (0) 0/11 (0) 4/40 (10)
Diary cards 5/71 (7) 2/25 (8) 2/15 (13) 0/25 (0) 0/15 (0) 0/11 (0) 4/40 (10)
Symptom-recording applications or telemedicine platforms 19/71 (27) 10/25 (40) 4/15 (27) 3/25 (12) 10/15 (67) 3/11 (28) 5/40 (13)
Adherence evaluation 30/71 (42) 9/25 (36) 7/15 (47) 10/25 (40) 5/15 (33) 4/11 (36) 17/40 (43)
Acceptability of virtual clinics
As good as face-to-face clinics 3/71 (4) 1/25 (4) 1/15 (7) 0/25 (0) 2/15 (13) 0/11 (0) 1/40 (3)
Somehow compromised, but still acceptable 27/71 (38) 8/25 (32) 6/15 (40) 11/25 (44) 4/15 (27) 3/11 (28) 18/40 (45)
Only viable for a short period of time 34/71 (48) 12/25 (48) 7/15 (47) 12/25 (48) 7/15 (47) 5/11 (46) 19/40 (48)
Unsatisfactory, low-quality medical advice 3/71 (4) 2/25 (8) 1/15 (7) 0/25 (0) 1/15 (7) 1/11 (9) 1/40 (3)
ACQ, Asthma Control Questionnaire; ACT, Asthma Control Test.
Values are n (%).











































TABLE II. Pediatric asthma burden during the COVID-19 pandemic




P<10 10-100 >100 Primary Secondary Tertiary
No. of participants contributing data, N 61 22 10 23 13 9 34
Asthma control: What percentage of your
pediatric asthma patients are currently
Well controlled 70 (60-80) 80 (70-90) 70 (60-85) 60 (50-80) <.01 80 (80-90) 70 (65-80) 70 (60-80)
Partially controlled 20 (10-30) 20 (10-20) 20 (15-30) 20 (20-30) 20 (10-20) 20 (20-35) 20 (10-30)
Uncontrolled 10 (0-10) 10 (0-10) 10 (0-10) 10 (10-20) 0 (0-10) 10 (10-15) 10 (10-13)
Asthma control: How does the current
control of your patients compare with
your expectations for these patients?
Better than expected 20 (10-40) 30 (10-50) 20 (10-25) 20 (10-40) 35 (20-43) 25 (10-48) 20 (10-30)
As expected 85 (70-100) 90 (65-100) 80 (70-95) 80 (70-100) 90 (65-100) 90 (75-100) 80 (70-100)
Worse than expected 10 (8-13) 10 (0-10) 10 (10-10) 10 (10-20) 0 (0-8) 10 (3-18) 10 (10-20) .03
Risk ratio of better vs worse asthma control,
RR (99% CI)
2.69 (2.17-3.34) 5.19 (3.06-8.81) 2.90 (1.89-4.47) 1.99 (1.50-2.64) 12.67 (5.29-30.32) 4.00 (1.30-12.33) 2.07 (1.65-2.61)
What proportion of your patients required a
change in their asthma treatments?
Treatment escalation 10 (10-30) 10 (10-30) 10 (10-20) 20 (10-25) 10 (10-30) 15 (10-30) 10 (10-30)
Unchanged treatment 80 (60-90) 80 (60-90) 80 (80-85) 80 (60-90) 90 (70-90) 80 (65-90) 80 (60-90)
Treatment de-escalation 10 (0-20) 10 (0-20) 10 (0-10) 10 (0-20) 10 (0-10) 10 (5-15) 10 (0-20)
Risk ratio escalation vs deescalation, RR
(99% CI)
1.41 (1.21-1.65) 1.78 (1.27-2.50) 5.21 (3.15-8.60) 0.95 (0.79-1.16) 2.22 (1.52-3.25) 2.42 (1.05-5.55) 1.24 (1.04-1.47)
Have you observed changes in the adherence
to controller medications?
Increased adherence 20 (10-43) 20 (10-30) 25 (13-38) 30 (10-50) 30 (20-45) 10 (8-15) 20 (10-50)
Unchanged adherence 80 (60-100) 90 (70-100) 80 (60-100) 70 (53-100) 70 (65-95) 100 (95-100) 80 (50-100) .03
Reduced adherence 10 (0-10) 10 (0-10) 10 (5-10) 10 (0-30) 10 (3-10) 0 (0-3%) 0 (0-18%)
Risk ratio of increased vs reduced adherence,
RR (99% CI)
1.97 (1.66-2.33) 3.00 (2.01-4.47) 3.79 (2.41-5.98) 1.43 (1.16-1.77) 3.11 (2.08-4.64) 6.00 (0.38-94.23) 1.73 (1.43-2.09)
Limited availability/access to asthma
medications, n (%)
21/69 (30) 8/25 (32) 2/15 (33) 9/25 (36) 6/15 (40) 3/11 (28) 12/42 (29)
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participating centers
Suspected cases of COVID-19 in children with asthma were
reported in only 13 of 91 participating centers (14%). There
were 100 such cases (a median of 3 suspected cases in each of
these centers; IQR, 2-10). Of these, only 15 (15%) were
confirmed, 10 in 1 center in Italy, 2 in Portugal, and the
remaining in 2 French centers. The most frequent presenting
symptoms of the confirmed cases included nasal discharge or
blockage and cough, whereas breathlessness, fever, and wheeze
were less often reported (see details in Table E5 in this article’s
Online Repository at www.jaci-inpractice.org). Half the reported
cases also experienced nonrespiratory symptoms, such as myalgia
and fatigue. Eleven of these children (73%) experienced a mild
clinical syndrome, 3 (20%) a moderate illness, and only 1 case
(6.7%) required hospitalization. None required an admission to
the intensive care unit or ventilation, and all made a complete
recovery.DISCUSSION
There is no doubt that pediatric asthma clinics are among
health care services significantly affected by the COVID-19
pandemic. The number of new patients evaluated is
restricted, while there is also a reduction in the frequency and/
or the total number of patients monitored. In addition, use of
several diagnostic modalities, including lung function testing,
fractional exhaled nitric oxide, or methacholine tests, is limited,
along with therapeutic interventions, such as nebulized treat-
ments.16 However, many services have actively responded to
these challenges, most often by “virtual” clinics or other tele-
health appliances, which flourished in all medical specialties
during the COVID-19 epidemic.17 Clinicians consider such
clinics suboptimal, nonetheless adequate for the, hopefully,
short time period under lockdown. Standard tools such as the
Asthma Control Test or the Asthma Control Questionnaire
were used, whereas objective measures, such as spirometry or
peak expiratory flow rate, were less often feasible. The observed
approaches are consistent with recent ad-hoc
recommendations.18
Despite the above challenges, there was no apparent deterio-
ration in asthma in the large majority of patients. In fact, based
on the perceptions of the participants, improvement exceeded
expectations in 20% of subjects. This was accompanied, and
possibly partially mediated, by increased adherence to treatment
plans—normally a major challenge in pediatric asthma man-
agement. Contrasting and very often unproven information has
been circulated through the media in regard to maintenance
medications and management. Among others, inhaled and/or
systemic corticosteroids have been of particular interest, as both a
potential COVID-19 treatment and as an increased susceptibility
factor.19 Our findings suggest that parents of children with
asthma monitored in specialist clinics have responded to mes-
sages on the need for treatment continuation, rather than un-
founded fears about potentially detrimental effects of inhaled
steroids. Furthermore, social distancing, sheltering at home, and
reduced school days may reduce exposure to the main triggers of
acute asthma events, most notably rhinovirus infections, outdoor
allergens, physical exercise, and air pollution,20,21 contributing to
sustained, or even improved, outcomes during this period.
Nevertheless, a small proportion of children (w10%) havedeteriorated; confinement in children sensitized to indoor aller-
gens and/or psychological factors may have contributed to this.
Despite the differences between countries regarding COVID-
19 infection and policies, the number of pediatric patients with
asthma with suspected and, even more, confirmed COVID-19
was small, coming mostly from 1 tertiary center in Italy. It is
noteworthy that even in these cases, the clinical course was
benign, and wheezing, the hallmark of asthma, was observed in
only 40%, while the simultaneous presence of other viruses was
not assessed.
Our data cannot provide a concrete estimate of the clinically
relevant COVID-19 incidence among children with asthma.
However, taking into account (1) the reported COVID-19
incidence in the more severely affected countries (the United
States, Spain, Italy, France, and the United Kingdom; 2.2-4.8
cases per thousand population22) and (2) data suggesting that
COVID-19, severe enough to lead to seeking medical advice and
thus diagnosed, is about 12.8 times less frequent in children than
in adults,3 17 to 38 such cases per 100,000 of a nonselected
pediatric population can be assumed. This is consistent with
recent data on the burden of COVID-19 in children in China,
South Korea, and the United States, where it is uniformly very
low.3,23,24 In our survey, the estimated population of pediatric
patients with asthma represented within these countries was
20,000 to 40,000; that is, the expected range of potential pa-
tients with COVID-19 would be 3 to 15, suggesting that
COVID-19 is not associated with severe asthma exacerbations.
It is possible that SARS-CoV-2 does not induce bronchial
hyperreactivity and asthma-like pathophysiology; nevertheless,
this does not exclude the possibility of children with asthma,
particularly uncontrolled asthma, developing more severe
COVID-19, as we have previously reported for influenza.25
Furthermore, the impact of atopy on SARS-CoV-2 susceptibil-
ity needs to be further evaluated, in light of recent findings
suggesting that allergic sensitization and allergen exposure may
reduce the SARS-CoV-2 receptor, angiotensin-converting
enzyme 2.26 However, only 1 case requiring hospitalization
was identified through this survey, drawing information from a
large number of children with asthma, including a large pro-
portion with severe asthma, given the large proportion of re-
spondents from tertiary centers. Further evaluation of children
with asthma, poor symptom control, and high severity in regard
to the individual response to SARS-CoV-2 will be needed to
draw a firm conclusion.
There are several limitations to this survey. Most importantly,
the clinical data that are described are not based on direct eval-
uation of patients, but on the subjective evaluation of the re-
spondents and therefore, there is a risk of recall bias. In addition,
respondents might have been unaware of some of the acute
presentations of their patients to alternative clinical sites. How-
ever, clinicians are well aware of this issue that is not specific to
the COVID-19 era. There is a chance that changes in clinical
practice due to COVID-19 may have led more patients to seek
medical advice from alternative sources; however, all partici-
pating centers offered either physical or virtual appointments or
helplines for patients with acute symptoms.
In parallel, children with asthma tend to have less controlled
disease at the time of the initial referral to the expert clinic.
Therefore, the significant decrease in new referrals may partially
account for the respondents’ perception that asthma control has
improved during the pandemic. However, clinicians were
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control among patients during monitoring visits, during versus
before the epidemic. As a result of these limitations, all findings
described about the clinical burden of COVID-19 on children
with asthma should be considered exploratory and further studies
directly evaluating the clinical course of children with asthma are
needed.
Moreover, responders are clinicians with high expertise and
interest in the domain; therefore, they may not be representative
of all pediatric asthma services. Nevertheless, our findings of
limited COVID-19 burden within the included cohorts that are
potentially selective for children with more severe or uncon-
trolled asthma, including patients treated with biologics, further
supports our conclusions. Moreover, expertise and increased
interest, as confirmed by the rapid response of the totality of
invited, may also be considered a strong point. Input came from
a wide geographical spread; unfortunately, Africa and Oceania
were minimally represented. Similarly, the responses do not
include many low-income countries, in which health services,
underlying susceptibility to illness, and disease impact may be
different.
CONCLUSIONS
Children with asthma do not appear to be disproportionately
affected by COVID-19; relevant high-end services have rapidly
responded, medication adherence has not been negatively
affected, and outcomes are promising. Ongoing epidemiological
studies, including one initiated by this group, will be able to
quantify any added and long-term risk of COVID-19 on chil-
dren with asthma.
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Q1. Does your Pediatric Asthma clinic continue to run physically?
Yes
No









Q4. Do you offer a virtual (online or telephone) clinic/consultation?
Yes
No




Q6. Approximately how many patients do you see per week (number)?
Number: _______
Q7. Has the type/severity/priority of patients changed?
No
Yes—more severe
Yes—patients receiving biologicals only
Yes—other priority please specify
Q8. Which of the following methods do you use to monitor your patients?
A standardized questionnaire
An asthma control test (ACT, ACQ, other)






Q9. What has been your experience with your virtual clinic so far?
As good as the face-to-face clinic
Somehow compromised but still okay
Only viable for a short period of time
Unsatisfactory—low-quality medical service
Other (please specify): _______
Q10. Do you offer a helpline for your pediatric asthma patients?
Yes
No
Q11. If you do not offer physical or virtual clinic, please describe
expectations/plans around pediatric asthma patients in the near
future.
Free text: __________










Q14. If yes, how many new patients do you receive every
week, during the COVID-19 pandemic?
Number: _____




Q16. If yes, how many?
Number: _____




Q18. Has any of your pediatric asthma patients had confirmed COVID?
No
Yes
Q19. If yes, approximately how many?
Number: _____
Q20. Their symptoms at presentation included:
Runny/blocked nose. Percentage: _____
Cough. Percentage: _____
Wheeze. Percentage: _____
Shortness of breath. Percentage: _____
Fever. Percentage: _____
Nonrespiratory symptoms/other. Percentage: _____
Q21. Their clinical course in regard to their asthma has been:
Mild. Percentage: _____
Moderate (treated at home). Percentage: _____
Severe exacerbation (emergency visit or hospital admission).
Percentage: _____
Required ICU admission or intubation. Percentage: _____
Death. Percentage: _____




Q23. If yes, approximately how many?
Number: _____
Q24. Their symptoms at presentation included:
Runny/blocked nose. Percentage: _____
Cough. Percentage: _____
Wheeze. Percentage: _____
Shortness of breath. Percentage: _____
Fever. Percentage: _____
Nonrespiratory symptoms/other. Percentage: _____
Q25. Their clinical course in regard to their asthma has been:
Mild. Percentage: _____
Moderate (treated at home). Percentage: _____
(continued)
TABLE E1. (Continued)
Severe exacerbation (emergency visit or hospital admission).
Percentage: _____
Required ICU admission or intubation. Percentage: _____
Death. Percentage: _____
Q26. In the last month, approximately how many patients have you
monitored (either physically or virtually)?
Number: _____
Q27. From the patients you have monitored, what is the proportion with
Well-controlled asthma. Percentage: _____
Partially controlled asthma. Percentage: _____
Uncontrolled asthma. Percentage: _____
Q28. How does this compare with your expectations for the same patients?
As expected. Percentage: _____
Better that expected. Percentage: _____
Worse than expected. Percentage: _____
Q29. What was the proportion of patients with regard to treatment
changes?
Increased treatment. Percentage: _____
Continued treatment. Percentage: _____
Decreased treatment. Percentage: _____
Q30. Is availability or access to medication an issue?
Yes
No
Q31. Have you observed changes in adherence to controller medications?
No changes in adherence. Percentage: _____
Increased adherence. Percentage: _____
Reduced adherence. Percentage: _____
Any comment on adherence changes? _____
Q32. Number of your patients (approximately) who have suffered an
exacerbation during the last month and treated at outpatients
(independent of COVID)?
Number: _____
Q33. Number of your patients (approximately) who have suffered an
exacerbation during the last month and were hospitalized
(independent of COVID)?
Number: _____
Q34. In which country do you practice?





Q36. Your email (optional)
Q37. Your name (optional)
ACQ, Asthma Control Questionnaire; ACT, Asthma Control Test; ICU, intensive
care unit.



































TABLE E3. Respondent distribution by domain
Domains Participants
Setting Tertiary/university hospital (47)
Secondary care (11)
Primary care, private practice (15)
Not declared (18)
COVID burden <10 deaths per million population (31)
10-100 deaths per million population (15)





Upper middle income (19)
Low middle income (4)
Not declared (19)
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TABLE E4. Pediatric patients with asthma reviewed by the participating centers, in the past and during the COVID-19 pandemic
Patients reviewed Overall cohort
COVID-19 burden (deaths/million) Clinical setting
<10 10-100 >100 Primary Secondary Tertiary
No. of consultations per respondent
per week, median (IQR)
20 (10-25) 12.5 (5-20) 18 (14-28) 20 (10-25) 20 (10-25) 5 (5-10) 20 (11-24)
No. of participants contributing data, N 61 22 10 23 13 9 34
Total no. of patients
evaluated weekly by respondents, N
1,727 326 301 785 292 69 1081
Annualized estimate of patients evaluated, N 89,804 16,952 15,652 40,820 15,184 3,588 56,212
No. of patients evaluated per respondent
during the preceding month, median (IQR)
35 (20-60) 25 (10-40) 38 (21-60) 48 (20-68) 50 (10-100) 25 (10-30) 40 (20-60)
No. of participants contributing data, N 59 22 14 22 13 9 37
Total no. of patients evaluated during the
preceding month by participants, N
3,593 820 728 1,925 870 214 2,509
Annualized estimate of patients evaluated, N 43,116 9,840 8,736 23,100 10,440 2,568 30,108
No. of new patients per respondent per week,
during COVID-19, median (IQR)
5 (3-9) 3.5 (2-5) 4 (3-6) 5 (3-10) 5 (2-8) 4 (4-5) 5 (3-10)
No. of participants contributing data, N 27 10 4 9 8 2 14
Total no., N 194 63 20 74 62 8 97
No. of patients receiving
biologics in the clinic, median (IQR)
11 (5-20) 5 (3-10) 9 (5-15) 20 (10-30) 10 (5-17) 3 (3-3) 11 (6-20)
No. of participants contributing data, N 38 8 9 20 4 1 32
TABLE E5. Clinical presentation of children with asthma and
confirmed COVID-19
Symptoms No. (proportion)
Nasal discharge or blockage 9 of 15 (60%)
Cough 11 of 15 (73%)
Wheeze 6 of 15 (40%)
Breathlessness 6 of 15 (40%)
Fever 6 of 15 (40%)
Nonrespiratory symptoms 9 of 15 (60%)
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